ALHC vs. NVO: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and NVO, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
NVO stands out with 305.18 billion USD in market value—about 100.62× ALHC’s market cap of 3.03 billion USD.
ALHC’s beta of 1.33 points to much larger expected swings compared to NVO’s calmer 0.21, suggesting both higher upside and downside potential.
NVO is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ALHC, which is purely domestic.
| Symbol | ALHC | NVO |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | Novo Nordisk A/S |
| Country | US | DK |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Drug Manufacturers - General |
| CEO | Mr. John E. Kao | Mr. Lars Fruergaard Jorgensen |
| Price | 15.33 USD | 68.2 USD |
| Market Cap | 3.03 billion USD | 305.18 billion USD |
| Beta | 1.33 | 0.21 |
| Exchange | NASDAQ | NYSE |
| IPO Date | March 26, 2021 | April 30, 1981 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ALHC and NVO over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and NVO based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALHC posts a negative P/E of -32.75, reflecting last year’s net loss, while NVO at 18.77 signals healthy earnings.
- ALHC posts a negative forward PEG of -1.11, hinting at anticipated earnings decline, whereas NVO at 1.31 has projections for stable or growing earnings.
| Symbol | ALHC | NVO |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | 18.77 |
| Forward PEG Ratio (TTM) | -1.11 | 1.31 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 6.53 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 14.17 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | 26.48 |
| EV-to-EBITDA (TTM) | -64.47 | 12.80 |
| EV-to-Sales (TTM) | 0.86 | 6.79 |
| EV-to-Free Cash Flow (TTM) | 136.01 | 27.55 |
Dividend Comparison
ALHC offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while NVO provides a 2.58% dividend yield, giving investors a steady income stream.
| Symbol | ALHC | NVO |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.58% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and NVO, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- NVO’s current ratio of 0.74 indicates its assets may not cover near-term debts, whereas ALHC at 1.69 maintains healthy liquidity.
- NVO posts a quick ratio of 0.56, indicating limited coverage of short-term debts from its most liquid assets—while ALHC at 1.69 enjoys stronger liquidity resilience.
- With negative EBIT (-2.98), ALHC cannot cover its interest payments. NVO, with an interest coverage of 17.84, meets its interest obligations.
| Symbol | ALHC | NVO |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 0.74 |
| Quick Ratio (TTM) | 1.69 | 0.56 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 0.86 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.24 |
| Interest Coverage Ratio (TTM) | -2.98 | 17.84 |